Veru Inc. (NASDAQ:VERU) Receives $25.00 Average PT from Analysts

Veru Inc. (NASDAQ:VERU) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $25.00.

A number of analysts recently issued reports on VERU shares. Wall Street Zen raised Veru from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research report on Wednesday, October 8th. Oppenheimer restated an “outperform” rating on shares of Veru in a report on Thursday. Finally, Canaccord Genuity Group initiated coverage on shares of Veru in a report on Thursday, December 18th. They issued a “buy” rating and a $25.00 target price for the company.

Veru Stock Performance

Shares of Veru stock opened at $2.29 on Friday. The stock has a 50 day moving average of $2.86 and a 200 day moving average of $4.03. The firm has a market capitalization of $36.75 million, a price-to-earnings ratio of -1.04 and a beta of -1.00. Veru has a fifty-two week low of $2.11 and a fifty-two week high of $14.20.

Hedge Funds Weigh In On Veru

Several hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. purchased a new position in Veru during the 3rd quarter valued at about $110,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Veru during the third quarter worth about $38,000. Choreo LLC acquired a new stake in shares of Veru during the third quarter worth about $287,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Veru in the third quarter valued at approximately $47,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Veru in the third quarter valued at approximately $616,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.